Last reviewed · How we verify
NCT03681249
the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD
EARLY_PHASE1 trial testing ShenqiDihuang Decoction in Diabetic Nephropathy Type 2 in 112 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Shanghai University of Traditional Chinese Medicine |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 112 |
| Start date | 2 November 2018 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- ShenqiDihuang Decoction — full drug profile →
- ShenqiDihuang Decoction placebo
Conditions studied
- Diabetic Nephropathy Type 2 — all drugs for Diabetic Nephropathy Type 2 →
Sponsor
Shanghai University of Traditional Chinese Medicine
Who can join
Adults 18 to 75, any sex, with Diabetic Nephropathy Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Efficacy and Safety of treatment with Traditional Chinese Medicine ShenqiDihuang Decoctions in Patients with middle stage of Diabetic Kidney Disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03681249
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Nephropathy Type 2
Currently open trials in the same condition.
- NCT06586203 — Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes · NA · recruiting
- NCT05888909 — Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy · recruiting
- NCT06833541 — Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease · recruiting
- NCT04931537 — Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics. · recruiting
- NCT04573920 — Atrasentan in Patients With Proteinuric Glomerular Diseases · Phase 2 · active not recruiting
Other Shanghai University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07331740 — Development and Application of a Parenting Anxiety Intervention Program for Young and Middle-Aged Female Breast Cancer P · NA · not yet recruiting
- NCT07069049 — Electroacupuncture in the Treatment of Patients Undergoing Transperineal Prostate Biopsy Under Local Anesthesia · NA · not yet recruiting
- NCT07245342 — Electroacupuncture for Improving Urinary Incontinence After Radical Prostatectomy · NA · not yet recruiting
- NCT06921512 — TCM Daoyin for Anxiety/Depression: Psychological Effects and Biological Mechanisms · NA · recruiting
- NCT06690606 — EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03681249 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai University of Traditional Chinese Medicine
- Last refreshed: 6 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03681249.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing